UBP 302
UBP 302 structure
|
Common Name | UBP 302 | ||
|---|---|---|---|---|
| CAS Number | 745055-91-8 | Molecular Weight | 333.29600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H15N3O6 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of UBP 302UBP 302, the S enantiomer, is a potent and selective GluK1 (GluR5)-subunit containing kainate receptor antagonist (apparent Kd=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects[1][2][3]. |
| Name | 2-[[3-[(2S)-2-amino-2-carboxyethyl]-2,6-dioxopyrimidin-1-yl]methyl]benzoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | UBP 302, the S enantiomer, is a potent and selective GluK1 (GluR5)-subunit containing kainate receptor antagonist (apparent Kd=402 nM), and displays very little affinity on GluK2 (GluR6) kainate receptors. Anxiolytic effects[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Apparent Kd: 402 nM (GluK1)[2] IC50: 106 μM (AMPA receptors)[2] |
| References |
| Molecular Formula | C15H15N3O6 |
|---|---|
| Molecular Weight | 333.29600 |
| Exact Mass | 333.09600 |
| PSA | 144.62000 |
| InChIKey | UUIYULWYHDSXHL-NSHDSACASA-N |
| SMILES | NC(Cn1ccc(=O)n(Cc2ccccc2C(=O)O)c1=O)C(=O)O |
|
The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.
J. Pharmacol. Exp. Ther. 351(2) , 359-72, (2014) Exposure to nerve agents induces prolonged status epilepticus (SE), causing brain damage or death. Diazepam (DZP) is the current US Food and Drug Administration-approved drug for the cessation of nerv... |
|
|
High-Throughput Screen of GluK1 Receptor Identifies Selective Inhibitors with a Variety of Kinetic Profiles Using Fluorescence and Electrophysiology Assays.
J. Biomol. Screen. 20 , 708-19, (2015) GluK1, a kainate subtype of ionotropic glutamate receptors, exhibits an expression pattern in the CNS consistent with involvement in pain processing and migraine. Antagonists of GluK1 have been shown ... |
|
|
A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.
Toxicol. Appl. Pharmacol. 284 , 204-16, (2015) Inhibition of acetylcholinesterase (AChE) after nerve agent exposure induces status epilepticus (SE), which causes brain damage or death. The development of countermeasures appropriate for the pediatr... |
| Tocris-2079 |
| UBC |
| (S)-1-(2-AMINO-2-CARBOXYETHYL)-3-(2-CARBOXYBENZYL)PYRIMIDINE-2,4-DIONE |
| UBP-302 |
| 2f35 |